Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,437 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,437 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03494569 | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell… | Phase 1 | suspended | Apr 11, 2018 | City of Hope Medical Center | Accrual goal | Enrollment / accrual |
| NCT05886491 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Jun 2, 2023 | Takeda | Sponsor decision (No safety concern) | Safety / toxicity |
| NCT06071624 | Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line… | Phase 1 | suspended | Oct 6, 2023 | Huda Salman | Trial being transferred to new lead site | Other (stated, no rule matched) |
| NCT06197672 | Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory… | Phase 1 | suspended | Jan 9, 2024 | Huda Salman | Trial being transferred to new lead site | Other (stated, no rule matched) |
| NCT06714591 | Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 | Phase 1 | terminated | Dec 3, 2024 | SystImmune Inc. | Sponsor prioritization of other development portfolio | Sponsor / business decision |
| NCT07052994 | A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab… | Phase 1 | withdrawn | Jul 8, 2025 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT04601584 | GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell… | Phase 1 / Phase 2 | terminated | Oct 26, 2020 | AO GENERIUM | The sponsor discontinued the development of the drug for reasons other than safety. | Safety / toxicity |
| NCT04021368 | RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome | Phase 1 | terminated | Jul 16, 2019 | Ryvu Therapeutics SA | RPD2 has been identified | Other (stated, no rule matched) |
| NCT06268574 | Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML(RIVER-52) | Phase 2 | terminated | Feb 20, 2024 | Ryvu Therapeutics SA | Sponsor decision | Sponsor / business decision |
| NCT06421155 | Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia | N/A | suspended | May 20, 2024 | Case Comprehensive Cancer Center | Voluntary hold by PI | Other (stated, no rule matched) |
| NCT07313592 | Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients | — | suspended | Jan 2, 2026 | Washington University School of Medicine | Admin review | Other (stated, no rule matched) |
| NCT06597734 | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in… | Phase 2 | withdrawn | Sep 19, 2024 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | Phase 2 | suspended | Nov 8, 2024 | Leland Metheny | insufficient funding | Funding |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant… | Phase 1 / Phase 2 | terminated | Nov 25, 2024 | BlueSphere Bio, Inc | Company Decision | Sponsor / business decision |
| NCT07566585 | Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute… | Phase 1 | withdrawn | May 5, 2026 | BlueSphere Bio, Inc | Company Decision | Sponsor / business decision |
| NCT07338357 | Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML | Early Phase 1 | withdrawn | Jan 13, 2026 | First Affiliated Hospital of Guangxi Medical University | Strategic adjustment. | Sponsor / business decision |
| NCT06514261 | Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs… | Phase 1 | suspended | Jul 23, 2024 | National Cancer Institute (NCI) | Other - Pending amendment for study expansion. | Other (stated, no rule matched) |
| NCT04010877 | Multiple CAR-T Cell Therapy Targeting AML | Phase 1 / Phase 2 | terminated | Jul 8, 2019 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05262673 | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL | Phase 1 | terminated | Mar 2, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05277753 | NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL | Phase 1 | terminated | Mar 14, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05780879 | A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission… | Phase 2 | terminated | Mar 23, 2023 | University of Michigan Rogel Cancer Center | Interim Analysis per Protocol | Efficacy / futility |
| NCT06802523 | Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and… | Phase 1 | suspended | Jan 31, 2025 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT03728335 | Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation | Phase 2 | suspended | Nov 2, 2018 | City of Hope Medical Center | Accrual goal met | Enrollment / accrual |
| NCT02392572 | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | M.D. Anderson Cancer Center | \<75% participants | Other (stated, no rule matched) |
| NCT07556757 | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic… | Phase 1 | terminated | Apr 29, 2026 | ImmunityBio, Inc. | Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug | Safety / toxicity |
| NCT06703216 | Pre-emptive Anakinra for Cytokine Event Reduction(PACER) | Phase 1 / Phase 2 | withdrawn | Nov 25, 2024 | Kevin McNerney | The trial has been stopped pending FDA approval of modifications to the trial protocol. | Other (stated, no rule matched) |
| NCT06492707 | DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse… | Phase 1 | suspended | Jul 9, 2024 | Fred Hutchinson Cancer Center | Recruitment on hold with plans to open to accrual again soon. | Enrollment / accrual |
| NCT04994808 | Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem… | Phase 2 | terminated | Aug 6, 2021 | Fred Hutchinson Cancer Center | The study was closed due to the end of funding. | Funding |
| NCT06903702 | A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years… | Phase 2 | withdrawn | Apr 1, 2025 | Memorial Sloan Kettering Cancer Center | Lack of funding | Funding |
| NCT03488225 | Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute… | Phase 2 | terminated | Apr 4, 2018 | M.D. Anderson Cancer Center | the study was closed early due to competing trials | Other (stated, no rule matched) |
| NCT06021600 | A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to… | Phase 1 | terminated | Sep 1, 2023 | M.D. Anderson Cancer Center | Slow participant enrollment | Enrollment / accrual |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT03969446 | Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute… | Phase 1 | suspended | May 31, 2019 | City of Hope Medical Center | Accrual goal Met | Enrollment / accrual |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming… | Phase 1 | suspended | Jun 1, 2022 | David Wald | Drugs unavailable | Other (stated, no rule matched) |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | Phase 1 | terminated | Apr 25, 2023 | BeOne Medicines | This decision is due to a company business decision with strategy change on the BGB-21447… | Safety / toxicity |
| NCT03874858 | A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia(DANTE) | Phase 2 | terminated | Mar 14, 2019 | Novartis Pharmaceuticals | Sponsor decision: The primary endpoint of the core/TF1 was achieved, and the sample size of… | Safety / toxicity |
| NCT06158100 | Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte… | Phase 1 | terminated | Dec 6, 2023 | Antonio M Jimenez Jimenez | Funding Sponsor decision due to review of efficacy data from other trials involving investigational… | Efficacy / futility |
| NCT03766126 | Lentivirally Redirected CD123 Autologous T Cells in AML | Phase 1 | terminated | Dec 6, 2018 | University of Pennsylvania | Administrative reasons. | Other (stated, no rule matched) |
| NCT05086315 | First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult… | Phase 1 / Phase 2 | terminated | Oct 20, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT07084584 | ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute… | Phase 1 | withdrawn | Jul 24, 2025 | Galecto Biotech AB | Study withdrawn due to business priority changes | Sponsor / business decision |
| NCT05716009 | Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab…(GO-TAG) | Phase 1 | terminated | Feb 8, 2023 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Upon analysis of the first 7 participants accrued, it was determined that this combination… | Enrollment / accrual |
| NCT02903277 | National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With… | — | withdrawn | Sep 16, 2016 | Centre Hospitalier Universitaire de Nice | L'investigateur est parti du CHU de Nice | Other (stated, no rule matched) |
| NCT05744739 | Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 1 | terminated | Feb 27, 2023 | Northwestern University | Premature withdrawal of investigational product per study sponsor. | Other (stated, no rule matched) |
| NCT03146871 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or… | Phase 2 | terminated | May 10, 2017 | University of Southern California | Lack of funding | Funding |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk… | Phase 1 / Phase 2 | terminated | Sep 16, 2020 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05712278 | A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in… | Phase 1 | terminated | Feb 3, 2023 | Sanofi | Sponsor's decision | Sponsor / business decision |
| NCT06447987 | Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed… | Phase 1 | suspended | Jun 7, 2024 | City of Hope Medical Center | Pending Interim Analysis | Efficacy / futility |
| NCT06630221 | Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations | Phase 2 | suspended | Oct 8, 2024 | Abhay Singh, MD MPH | Funding unavailable | Funding |
| NCT04161885 | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine…(VIALE-T) | Phase 3 | terminated | Nov 13, 2019 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04250051 | Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or… | Phase 1 | terminated | Jan 31, 2020 | Northwestern University | Low accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 21 hours agoSource updated Sep 28, 2026source: clinicaltrials